CBSC (Cardiac Biotech Solutions) Current Accrued Expense: $1.22 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Current Accrued Expense?

Cardiac Biotech Solutions CBSC Current Accrued Expense is $1.22 Mil as of Jun. 2025.

Cardiac Biotech Solutions's Current Accrued Expense for the quarter that ended in Jun. 2025 was $1.22 Mil.

Cardiac Biotech Solutions's quarterly Current Accrued Expense increased from Sep. 2024 ($0.85 Mil) to Mar. 2025 ($1.08 Mil) and increased from Mar. 2025 ($1.08 Mil) to Jun. 2025 ($1.22 Mil).

Cardiac Biotech Solutions's annual Current Accrued Expense increased from Mar. 2023 ($0.16 Mil) to Mar. 2024 ($0.61 Mil) and increased from Mar. 2024 ($0.61 Mil) to Mar. 2025 ($1.08 Mil).

Cardiac Biotech Solutions Current Accrued Expense Related Terms

Cardiac Biotech Solutions Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Current Accrued Expense Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Current Accrued Expense
0.10 0.11 0.16 0.61 1.08

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.73 0.85 1.08 1.22

Cardiac Biotech Solutions Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.22 Mil mean?
Cardiac Biotech Solutions (CBSC) has a Current Accrued Expense of $1.22 Mil as of Jun. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Current Accrued Expense too high?
Cardiac Biotech Solutions' current Current Accrued Expense is $1.22 Mil.
How does Cardiac Biotech Solutions' Current Accrued Expense compare to LUCY and NXGL?
Cardiac Biotech Solutions' Current Accrued Expense of $1.22 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Current Accrued Expense is $1.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Current Accrued Expense of $1.22 Mil. The current Current Accrued Expense is $1.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Current Accrued Expense is $1.22 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.